Solid Tumors
Why trials studying Solid Tumors stopped, in this sample of ClinicalTrials.gov.
19 stopped trials with a clear reason; 84% ended for non-scientific reasons.
| Reason | Trials | Share |
|---|---|---|
| funding business | 12 | 63% |
| slow accrual | 3 | 16% |
| futility | 2 | 11% |
| safety | 1 | 5% |
| manufacturing supply | 1 | 5% |
Trials
- A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers
NCT07176975 · SUSPENDED · funding business
“company decision” - A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors
NCT06158958 · TERMINATED · funding business
“Strategic considerations” - A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors
NCT04791228 · WITHDRAWN · slow accrual
“Low enrollment.” - A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors
NCT05129280 · TERMINATED · funding business
“The study was terminated due to program discontinuation.” - IBI188 Combination Therapy in Solid Tumors
NCT04861948 · TERMINATED · futility
“No signs of efficacy in solid tumors” - To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550
NCT04674748 · TERMINATED · funding business
“The study was terminated early due to a business decision.” - A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
NCT04029688 · TERMINATED · funding business
“Study was terminated by the sponsor based on insufficient tolerability and efficacy to proceed beyond Part 1b.” - A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
NCT03861403 · TERMINATED · funding business
“Product development discontinued unrelated to safety.” - A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)
NCT03347123 · TERMINATED · funding business
“A business decision made by Incyte after analysis of data from a sister study.” - Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
NCT03301896 · TERMINATED · funding business
“Business reasons” - A Study of PLX51107 in Advanced Malignancies
NCT02683395 · TERMINATED · funding business
“Business Decision” - Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma
NCT02110563 · TERMINATED · funding business
“Sponsor Decision” - ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
NCT02100007 · TERMINATED · futility
“lack of efficacy” - Phase Ib Study of Gemcitabine Plus Cisplatin or Carboplatin Plus Dovitinib in Patients With Advanced Solid Tumors
NCT01496534 · TERMINATED · safety
“toxicity of combination of medications” - A Study of DS-2248 in Participants With Advanced Solid Tumors
NCT01288430 · TERMINATED · funding business
“The trial was terminated as per Sponsor decision.” - Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Participants With Solid Tumors
NCT01190644 · TERMINATED · manufacturing supply
“Isotope needed to conduct RBC/PV analysis (primary endpoint) no longer available from manufacturer. No alternatives available for use.” - A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
NCT01369433 · TERMINATED · slow accrual
“Lack of new studies contributing subjects to this study” - Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors
NCT01127178 · TERMINATED · funding business
“Strategic decision, which is unrelated to safety” - Study to Evaluate the Effect of Age (Geriatric) and Kidney Function on the Safety, Efficacy and Pharmacokinetics of OctreoScan in Patients Who Have New or Recurrent Tumors
NCT00944372 · TERMINATED · slow accrual
“Enrollment was difficult”
Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.